Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Esophageal Squamous Cell Carcinoma 6Esophageal Neoplasms 6Nasopharyngeal Carcinoma 5Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Lymphoma 1Immunotherapy Esophagus Cancer 1Hypopharyngeal Neoplasms 1Hepatic Artery Infusion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 131Cetuximab 80Radiotherapy 76Docetaxel 59Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11130-nm albumin-bound paclitaxel 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × nedaplatin × Clear all
NCT02776163 2024-07-30

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 2 Completed
107 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡